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Objective: Cannabinoid receptors and their ligands have been implicated in the regulation of various
physiological processes but their role in osteoarthritis has not been investigated. The aim of this study
was to evaluate the role of the type 2 cannabinoid receptor (Cnr2) in regulating susceptibility to oste-
oarthritis in mice.
Methods: We analysed the severity of knee osteoarthritis as assessed by the Osteoarthritis Research
Society International (OARSI) scoring system in mice with targeted deletion of Cnr2 (Cnr2/) and wild
type (WT) littermates. Studies were conducted in mice subjected to surgical destabilisation of the medial
meniscus (DMM) and in those with spontaneous age-related osteoarthritis (OA).
Results: Osteoarthritis wasmore severe following DMM in themedial compartment of the knee in Cnr2/
comparedwithWTmice (mean± sem score¼ 4.9± 0.5 vs 3.6± 0.3; P¼ 0.017). Treatment ofWTmicewith
the CB2-selective agonist HU308 following DMM reduced the severity of OA in the whole joint
(HU308 ¼ 8.4 ± 0.2 vs vehicle ¼ 10.4 ± 0.6; P ¼ 0.007). Spontaneous age related osteoarthritis was also
more severe in the medial compartment of the knee in 12-month old Cnr2/ mice compared with WT
(5.6 ± 0.5 vs 3.5 ± 0.3, P ¼ 0.008). Cultured articular chondrocytes from Cnr2/ mice produced less
proteoglycans in vitro than wild type chondrocytes.
Conclusion: These studies demonstrate that the Cnr2 pathway plays a role in the pathophysiology of
osteoarthritis in mice and shows that pharmacological activation of CB2 has a protective effect. Further
studies of the role of cannabinoid receptors in the pathogenesis of osteoarthritis in man are warranted.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The endocannabinoid system has been implicated in the control
of a variety of physiological processes including the regulation of
appetite and energy balance; the perception of pain; and regulation
of the immune responses1. There are two classical cannabinoid
receptors which belong to the G-protein coupled receptor: S.H. Ralston, Rheumatology
xperimental Medicine, MRC
rsity of Edinburgh, Western
-651-1037; Fax: 44-131-651-
k (A. Sophocleous), anna.
alter@ed.ac.uk (D.M. Salter),
ternational. Published by Elsevier Lsuperfamily and signal through the Gi/o protein. The type 1
cannabinoid receptor (CB1), was ﬁrst to be identiﬁed. It is highly
expressed in the nervous system and mediates the psychotropic
and neurological effects of cannabinoids. The type 2 receptor (CB2)
is mainly expressed in peripheral tissues and has been implicated in
regulating the immunomodulatory effects of cannabinoids.
The best characterised endogenously produced cannabinoid
receptor ligands are N-arachidonoylethanolamine (anandamide)
and 2-arachidonoyl glycerol (2-AG) which are small molecules
produced by breakdown of membrane phospholipids. Both are
agonists at the type 1 and 2 cannabinoid receptors. The Cannabis
sativa plant contains a large number of cannabinoids but the best
known are D9-tetrahydrocannabinol, which acts as an agonist at
both receptors and is responsible for the psychotropic effects of
cannabis, and cannabidiol, which acts as an antagonist or inverse
agonist at CB1 and CB2 receptors. Many synthetic cannabinoidstd. All rights reserved.
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agonists at one or both cannabinoid receptors1. Cannabinoids have
been shown to interact with various other receptors including
GPR55, nicotinic acetyl choline receptors, calcium channels, voltage
gated potassium channels, and transient receptor potential vanil-
loid receptors1.
Over recent years there has been increasing interest in the po-
tential role of the endocannabinoid system in the pathophysiology
of bone and joint disease2. Previous studies have shown that mice
with targeted inactivation of the type 1 cannabinoid receptor
(Cnr1/mice) have increased peak bone mass due to an osteoclast
defect, but develop osteoporosis with increasing age due to
reduced bone formation3,4,5. Mice with targeted inactivation of the
type 2 cannabinoid receptor (Cnr2/ mice) have been reported to
have normal or slightly reduced peak bone mass but develop
osteoporosis with increasing age in associationwith increased bone
turnover6,7.
Cannabinoids and their receptors have also been implicated in
the pathogenesis of arthritis. For example, cannabidiol has been
shown to reduce cartilage damage in a mouse model of inﬂam-
matory arthritis8 and cannabinoid receptor agonists have been
found to protect against collagen-induced arthritis9 and to inhibit
IL-1 induced cartilage degradation in vitro10. Cannabinoid receptors
are expressed in articular chondrocytes10 and in human synovial
tissue11. Furthermore, 2-AG and anandamide have been detected in
synovial ﬂuid from humans with osteoarthritis (OA) and rheuma-
toid arthritis11. Given the importance of subchondral bone in the
pathogenesis of osteoarthritis12,13, the regulatory role of cannabi-
noid receptors in bone metabolism2 and the fact that CB2 is
expressed in chondrocytes and other joint tissues10,11 the aim of the
present study was to determine if the type 2 cannabinoid receptor
plays a role in the pathogenesis of osteoarthritis in mice.
Materials and methods
Materials
All reagents were obtained from Sigma Aldrich (Dorset, UK)
unless otherwise stated. The CB2-selective agonist HU308 was
purchased from Tocris Biosciences (Bristol, UK). Dulbecco's Modi-
ﬁed Eagle's Medium (D-MEM) was obtained from Invitrogen
(Paisley, UK), foetal calf serum was obtained from Fisher Scientiﬁc
(Leicestershire, UK), and L-glutamine and penicillin/streptomycin
were obtained from Invitrogen (Paisley, UK). Alcian Blue 8GX and
Safranin-O were purchased from TAAB Lab (Berkshire, UK), and
Harris Haematoxylin from Raymond A Lamb (Eastbourne, UK).
Animals
Mice targeted with inactivation of Cnr2, were generated as
previously described14 and were obtained from Dr Susana Winﬁeld
at the National Institutes of Health. Extensive previous studies have
been performed on this strain of mice (reviewed by Buckley15).
They have been reported to exhibit reduced bone density and
various other defects in responses to treatment with cannabinoid
receptor ligands including a reduced threshold for detection of
pain15. These mice are of normal size and body weight, reproduce
normally and have normal survival and locomotor activity. The
mice were backcrossed with wild type C57BL/6 mice for at least 10
generations to create Cnr2-deﬁcient mice (Cnr2/mice) on C57BL/
6 background. The wild type (WT) and Cnr2/ mice used in these
experiments were generated by mating heterozygote breeding
pairs. They were housed in pathogen-free rooms of a designated
animal facility, at constant temperature, under a 12-hour dark-to-light cycle with water and pelleted standard commercial diet
made available ad libitum. All animal experiments were approved
by the Animal Welfare and Ethical Review Body of the University of
Edinburgh and were conducted in accordance with the UK Animals
(Scientiﬁc Procedures) Act 1986.
Osteoarthritis induced by destabilisation of the medial meniscus
Osteoarthritis was induced in eight week old male mice by
surgically induced destabilisation of the medial meniscus (DMM)
essentially as described by Glasson et al.16 under general anaes-
thesia with ketamine hydrochloride 76 mg/kg and medetomidine
hydrochloride 1mg/kg given intraperitoneally. Following section of
the medial meniscotibial ligament, the joint capsule and skin were
the closed and anaesthesia reversed by an intraperitoneal injection
of atipamezole hydrochloride 1 mg/kg. Following DMM the mice
were followed up for eight weeks and killed at age 16 weeks by
inhalation of carbon dioxide. The lower limbs were carefully
dissected free, the skin was removed, and the limbs were ﬁxed for
24 h in 4% formaldehyde and then kept in ethanol (70% v/v) until
further analysis. We elected not to perform sham surgery on the
contralateral knee based on animal welfare grounds since previous
studies had shown no difference in OA scores between sham-
operated and non-operated knee joints using this model16,17 and
since the primary aim of the experiment research was to evaluate
the response to DMM in Cnr2/ and wild type mice. A total of nine
Cnr2/ and nine wild type mice were studied in this experiment.
Effect of the Cnr2 agonist HU308 on DMM induced osteoarthritis
We performed an additional DMM experiment in which eight
week old Cnr2/ and wild type mice were treated with the CB2-
selective agonist HU30818 or vehicle immediately after surgery.
The HU308 was initially dissolved in dimethylsulfoxide (DMSO)
and the DMSO/HU308 solution was dissolved in 5% (w/v) mannitol
and 0.5% (w/v) gelatin in distilled water. The HU308 was admin-
istered twice a week intraperitoneally at a ﬁnal dose of 1 mg/kg for
eight weeks. This dosage regimen was chosen since we have pre-
viously shown that it protects against ovariectomy induced bone
loss in mice7. The control group of mice received vehicle alone
intraperitoneally twice aweek for eight weeks. Both groups of mice
were then killed by inhalation of carbon dioxide at age 16 weeks
and the lower limbs were isolated as described above. A total of 11
mice were treated with vehicle (ﬁve WT and six Cnr2/ mice) and
12micewere treatedwith HU308 (sevenWTand ﬁve Cnr2/mice)
in this experiment.
Spontaneous age-related osteoarthritis
A third experiment was performed in which we compared the
severity of spontaneous age-related osteoarthritis in Cnr2/ and
wild type mice. For these experiments we performed histology and
MicroCT analysis of the knee joints of 12-month old female Cnr2/
mice and compared the ﬁndings with aged and gender matched
wild type littermates that had not undergone any speciﬁc experi-
mental procedures. The mice were killed by inhalation of carbon
dioxide, and the lower limbs were processed as described for the
DMM experiments. A total of ﬁve Cnr2/ and ﬁve wild type mice
were included in this experiment.
Analysis of periarticular bone by micro computed tomography
Analysis of periarticular bonewas performed bymicroCT using a
Skyscan 1172 instrument set at 60 kV and 167 mA, at a resolution of
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trabecular bone situated within the tibial epiphysis and the sub-
chondral bone plates of the tibial plateau (Supplementary Fig. 1).
The microCT analyses were performed in the coronal plane.
Following acquisition, the images were reconstructed using the
Skyscan NRecon programme and analysed using Skyscan CTAn
software.
Histological analysis
Histological analysis was performed on ﬁxed whole joints that
had been decalciﬁed in 10% formic acid for 1 week. The joints were
then processed and embedded in parafﬁn wax according to stan-
dard techniques. A Leica microtome (Solms, Germany) was used to
take 7 mm coronal sections through the entire joint at 45 mm in-
tervals, yielding 10e13 different levels. Sections were then stained
with Safranin-O and Haematoxylin according to standard tech-
niques. Histological evaluation of the severity of osteoarthritis was
performed by an observer (AS) blinded to genotype and pharma-
cological treatment according to the Osteoarthritis Research Soci-
ety International (OARSI) scoring system19. Scores were generated
from separately from the medial tibial plateau (MTP), the medial
femoral condyle (MFC), the lateral tibial plateau (LTP) and lateral
femoral condyle (LFC) (Supplementary Fig. 1). We then added the
scores from the tibial and femoral articular cartilage to give a
summated score for the medial and lateral compartments (ranging
from a minimum score of 0 to a maximum of 12). Finally we
calculated summated scores for the entire joint in which the scores
were combined from the medial and lateral compartments
(ranging from a minimum score of 0 to a maximum of score of 24).
A randomly selected sample of 26 joints were assessed by a
second observer (AEB) who was also blinded to genotype and
treatment allocation to test reproducibility of the scoring system.
Chondrocyte isolation from articular cartilage
Articular chondrocytes were isolated as previously described20.
We pooled the chondrocytes from several mice aged 5e6 days old,
for each experiment in order to obtain sufﬁcient numbers of cells.
Proteoglycan production by articular chondrocytes
Articular chondrocytes were cultured in gelatin-coated 12 well
plates at a density of 5  104 cells/well in standard D-MEM at 37C.
The mediumwas refreshed every 2 days for a total of 12 days when
cell number was determined by Alamar Blue staining as
described21. The cultures were then ﬁxed in 70% (v/v) ethanol and
stained for proteoglycans using 1% Alcian Blue in 0.1 M HCl. The
wells were washed to remove excess dye and 0.8 ml 4 M guanidine
HCl was added to each well to dissolve the dye. The plates were
incubated overnight at room temperature and the absorbance was
read at 600 nm on a microplate reader using an Alcian Blue dye
standard curve (concentration range 0e40 nM) prepared in the
same solvent22. The absorbance was corrected for cell number and
the amount of proteoglycan produced per cell was calculated in
arbitary units.
Statistical analysis and sample size
Statistical analyses were performed using IBM SPSS Statistics,
version 19 (Armonk, NY). The sample size for the initial DMM
experiment was chosen to provide 84% power to detect a 1.6
standard deviation difference in severity of osteoarthritis between
Cnr2/ and wild type mice. This effect size was chosen since wefelt that it was a biologically important difference. The sample size
for the HU308 experiment and the age-related experiment was
chosen to detect a two standard deviation difference between
groups. The inter-observer agreement between the OARSI scores of
AS and AEB was assessed by calculating the kappa co-efﬁcient. For
all experiments we determined if the data were normally distrib-
uted using the ShapiroeWilk test. For data that were normally
distributed, between group comparisons were performed by Stu-
dent's t-test. For data that were not normally distributed, com-
parisons were performed using the ManneWhitney U test. We
combined the results of the in vivo experiments by meta-analysis
using Review Manager version 5.3 software (Cochrane Collabora-
tion)23. Unless otherwise stated the values shown are themean and
standard error of mean (sem). The signiﬁcance level was set at
P  0.05 for individual experiments.
Results
Reproducibility of scoring system
Reproducibility of the OARSI scoring system used to assess
severity of OA was independently assessed by two observers (AS
and AEB) in 26 out of 106 samples (24.5%). This showed an inter-
observer kappa co-efﬁcient of 0.753 (P < 0.001), which is consid-
ered substantial24.
Effect of Cnr2 deﬁciency in DMM induced osteoarthritis
There was no signiﬁcant difference in OARSI scores for the non-
operated joints between Cnr2/ and WT mice [Fig. 1(A) and (B)].
The DMM operated joints showed a signiﬁcant increase in OARSI
score in the medial compartment when compared with the non-
operated joints. Values in the non-operated joint in wild type
mice were (mean ± sem) 1.6 ± 0.4 compared to 3.6 ± 0.3 in the
DMM operated joint representing a 124% increase (P < 0.001).
Corresponding values in Cnr2/ mice were 2.1 ± 0.7 in the non-
operated joint vs 4.9 ± 0.5 in the DMM operated joint represent-
ing a 134% increase (P¼ 0.002). There was no signiﬁcant increase in
OARSI score following DMM in the lateral compartment as
compared with the non-operated knee in either genotype group.
The OARSI scores were signiﬁcantly higher in the medial
compartment of DMMoperated Cnr2/micewhen comparedwith
wild type (4.9 ± 0.5 vs 3.6 ± 0.3, P ¼ 0.017) [Fig. 1(C) and (D)]. There
was no signiﬁcant difference in OARSI scores between genotype
groups in the lateral compartment [Fig. 1(C)] or when the scores
were combined for the whole joint (8.2 ± 0.9 vs 6.6 ± 0.9,
P ¼ 0.201). These results indicate DMM induces osteoarthritis
predominantly affecting the medial joint compartment and that
within this compartment Cnr2 deﬁciency is associated with
signiﬁcantly worse osteoarthritis than in wild type mice.
Effects of Cnr2 deﬁciency on subchondral bone in DMM induced
osteoarthritis
In order to determine if the predisposition to osteoarthritis
following DMM was associated with abnormalities in subchondral
bone we performed microCT analysis of tibial subchondral bone in
WTand Cnr2/mice. The results are summarised in Table I. In non-
operated joints, Cnr2/ mice had signiﬁcantly lower trabecular
number (Tb.N) (P ¼ 0.009), and increased trabecular separation
(Tb.Sp) than in WT mice (P ¼ 0.02) but none of the other param-
eters differed signiﬁcantly. In the joints undergoing DMM, trabec-
ular pattern factor (Tb.Pf) was slightly lower in Cnr2/ mice
compared with WT but the difference was not signiﬁcant. Analysis
Fig. 1. Response to DMM in wild type and Cnr2/ mice. Panel A shows OARSI scores from the femoral condyle and tibial plateau in the medial and lateral compartment of non-
operated knee joints of wild type (WT) and Cnr2/ mice. The maximum score for each compartment is 12. Panel C shows similar data in the medial and lateral compartment of
knee joints that underwent DMM. Panels B and D show representative photomicrographs from the non-operated and DMM operated joints, respectively. Areas of cartilage damage
at the tibial plateau (black arrows) and femoral condyle (red arrows) are indicated. Columns represent the mean and vertical bars the standard error of the mean from nine wild
type and nine Cnr2/ mice. The P-value refers to the difference between Cnr2/ and wild type mice as assessed by Student's t-test.
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tween genotypes and no signiﬁcant differences between non-
operated and DMM operated joints.
Effect of the Cnr2 agonist HU308 on DMM induced osteoarthritis
In view of the fact that Cnr2/ mice developed substantially
more severe osteoarthritis following DMM than wild type litter-
mates, we performed a further experiment to evaluate the effect
the CB2-selective agonist HU308 in the DMM model. For this
experiment Cnr2/ and wild type mice were administered HU308
or vehicle intraperitoneally at a dose of 1 mg/kg twice weekly forTable I
MicroCT analysis of tibial subchondral bone of wild type (WT) and Cnr2/ mice
Non-operated
WT (n ¼ 9) C
BV/TV (%) 25.09 ± 1.08
Tb.N (1/mm) 5.47 ± 0.16
Tb.Th (mm) 45.87 ± 1.33
Tb.Sp (mm) 163.09 ± 3.50 1
Tb.Pf (1/mm) 7.95 ± 1.32
Medial bone plate thickness (mm) 121.38 ± 10.07 1
Lateral bone plate thickness (mm) 86.67 ± 4.50
BV/TV: trabecular bone volume; Tb.N: trabecular number; Tb.Th: trabecular thickness; T
mean ± sem. *P ¼ 0.02 and **P ¼ 0.009 Cnr2/ vs wild type by Student's t-test.eight weeks following DMM. Administration of HU308 to WT mice
partially protected against the development of osteoarthritis in
both joint compartments. For the medial compartment the
mean ± sem OARSI score was 4.1 ± 0.2 in the HU308 group
compared with 5.4 ± 0.6 in the vehicle group (P ¼ 0.022) and
corresponding score in the lateral compartment was 4.3 ± 0.2 vs
5.0 ± 0.0, P ¼ 0.018) [Fig. 2(A) and (B)]. When the scores were
combined for both compartments, the difference between HU308
and vehicle treated mice was signiﬁcant (8.4 ± 0.2 vs 10.4 ± 0.6,
P ¼ 0.007).
In contrast, administration of HU308 to Cnr2/ mice had no
signiﬁcant protective effect on the severity of osteoarthritisDMM
nr2/ (n ¼ 9) WT (n ¼ 9) Cnr2/ (n ¼ 9)
23.81 ± 1.47 25.64 ± 0.83 25.79 ± 0.94
4.90 ± 0.12** 5.25 ± 0.14 5.27 ± 0.19
48.49 ± 2.34 48.85 ± 0.96 49.14 ± 1.68
77.62 ± 4.85* 169.63 ± 1.82 171.40 ± 3.22
8.76 ± 1.49 7.48 ± 1.55 3.81 ± 1.80
42.58 ± 10.06 137.38 ± 5.50 139.03 ± 10.45
92.30 ± 6.17 94.12 ± 2.73 100.84 ± 4.07
b.Sp: trabecular separation; Tb.Pf: trabecular pattern factor. The values shown are
Fig. 2. Effect of HU308 on osteoarthritis following DMM in wild type (WT) and Cnr2/ mice. Panel A shows OARSI scores from the femoral condyle and tibial plateau in the medial
and lateral compartments of knee joints in wild type (WT) mice following DMM and treatment with vehicle or HU308. The maximum score for each compartment is 12. Panel C
shows similar data from Cnr2/ mice. Panels B and D show representative photomicrographs from the operated joints in WT and Cnr2/ mice, respectively. Areas of cartilage
damage at the tibial plateau (black arrows) and femoral condyle (red arrows) are indicated. Columns represent the mean and vertical bars the standard error of the mean from ﬁve
vehicle-treated wild type mice, seven HU308-treated wild type mice, six vehicle treated Cnr2/ mice and ﬁve HU308 treated Cnr2/ mice. The P-values refer to differences
between the HU308 and vehicle treated mice as assessed by ManneWhitney U test.
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involved in the pathogenesis of osteoarthritis induced by DMM by
showing that HU308 protects from cartilage damage in wild type
mice but not in Cnr2/ mice.Effect of the Cnr2 agonist HU308 on subchondral bone in DMM
induced osteoarthritis
There was no signiﬁcant difference in the tibial subchondral
trabecular bone in mice treated with HU308 or placebo either be-
tween genotypes (Cnr2/ vs WT) or within genotypes with the
exception of Tb.Th which was slightly but signiﬁcantly higher inTable II
MicroCT analysis of tibial subchondral bone following HU308 or vehicle treatment
HU308
WT (n ¼ 7) C
BV/TV (%) 27.30 ± 0.98
Tb.N (1/mm) 6.45 ± 0.24
Tb.Th (mm) 42.44 ± 1.41
Tb.Sp (mm) 168.13 ± 6.36 1
Tb.Pf (1/mm) 7.69 ± 2.77
Medial bone plate thickness (mm) 71.57 ± 4.98
Lateral bone plate thickness (mm) 56.83 ± 2.19
BV/TV: trabecular bone volume; Tb.N: trabecular number; Tb.Th: trabecular thickness;
means ± sem. The number of mice in each group are indicated. * indicates P ¼ 0.015 CnHU308 treated Cnr2/ vs wild type mice (Table II). In addition,
HU308 treatment had no signiﬁcant effect on subchondral bone
plate thickness in either genotype group (Table II).Effect of Cnr2 on spontaneous age-related osteoarthritis
A further experiment was conducted to determine if Cnr2/
mice showed increased susceptibility to age related osteoarthritis.
Histological analysis showed that OARSI score in the medial
compartments of the knee joint was signiﬁcantly higher in Cnr2/
 mice than wild type littermates (5.6 ± 0.5 vs 3.5 ± 0.3,
P ¼ 0.008) [Fig. 3(A) and (B)]. There was no signiﬁcant differenceVehicle
nr2/ (n ¼ 5) WT (n ¼ 5) Cnr2/ (n ¼ 6)
28.19 ± 1.12 28.12 ± 1.05 29.24 ± 1.03
5.92 ± 0.23 6.38 ± 0.22 6.10 ± 0.36
47.67 ± 1.14* 44.22 ± 2.01 48.29 ± 1.86
74.26 ± 2.16 166.00 ± 4.41 170.70 ± 5.06
2.59 ± 2.18 6.12 ± 2.30 5.56 ± 3.32
76.65 ± 4.26 76.11 ± 6.25 78.79 ± 3.70
65.98 ± 5.14 61.22 ± 2.80 67.10 ± 4.83
Tb.Sp: trabecular separation; Tb.Pf: trabecular pattern factor. Data is presented as
r2/ vs wild type assessed by Student's t-test.
Fig. 3. Age-related osteoarthritis in wild type (WT) and Cnr2/ mice. Panel A shows
OARSI score from femoral condyle and tibial plateau in the medial and lateral com-
partments of knee joints in 12-month old wild type (WT) and Cnr2/ female mice. The
maximum score for each compartment is 12. Panel B shows representative photomi-
crographs from joints of WT and Cnr2/ mice. Areas of cartilage damage at the tibial
plateau (black arrows) and femoral condyle (red arrows) are indicated. Columns
represent the mean and vertical bars the standard error of the mean (sem) from ﬁve
wild type and ﬁve Cnr2/ mice. The P-value refers to the difference between Cnr2/
and wild type assessed by ManneWhitney U test.
Table III
MicroCT analysis of tibial subchondral bone in twelvemonth old wild type (WT) and
Cnr2/ mice
WT (n ¼ 5) Cnr2/ (n ¼ 5)
BV/TV (%) 14.82 ± 0.73 14.04 ± 0.36
Tb.N (1/mm) 2.77 ± 0.12 2.64 ± 0.13
Tb.Th (mm) 53.55 ± 1.74 53.48 ± 1.70
Tb.Sp (mm) 259.36 ± 7.36 272.13 ± 10.29
Tb.Pf (1/mm) 9.77 ± 1.74 9.18 ± 2.37
Medial bone plate thickness (mm) 141.89 ± 7.51 147.56 ± 6.01
Lateral bone plate thickness (mm) 116.15 ± 2.55 121.38 ± 6.12
BV/TV: trabecular bone volume; Tb.N: trabecular number; Tb.Th: trabecular thick-
ness; Tb.Sp: trabecular separation; Tb.Pf: trabecular pattern factor. Data is presented
as means ± sem. There was no signiﬁcant difference between genotype groups for
any variable.
Fig. 4. Proteoglycan production by WT and Cnr2/ chondrocytes. Panel A shows
proteoglycan deposition as assessed by Alcian blue staining from wild type (WT) and
Cnr2/ mice. Values are expressed as percent of the values observed in WT cultures.
Panel B representative photomicrographs from cultures described in A. Columns
represent means and vertical bars standard error of the mean from three separate
experiments. The P-value refers to the difference between wild type and Cnr2/
assessed by Student's t-test.
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OARSI scores were combined for both compartments the score
was signiﬁcantly higher in Cnr2/ mice as compared with wild
type (11.0 ± 0.8 vs 8.5 ± 1.0, P ¼ 0.043). There was no signiﬁcant
difference in body weight between Cnr2/ and wild type mice at
age 12 months or any other time point, nor was there any obvious
difference between genotypes in general health status, behaviour
or locomotor activity. These results provide further evidence that
Cnr2 deﬁciency is associated with an increased susceptibility to
osteoarthritis.
Effect of Cnr2 deﬁciency on subchondral bone in age related
osteoarthritis
Analysis of tibial subchondral trabecular bone of 12-month old
WT and Cnr2/ female mice showed no difference in any variable
between genotypes (Table III). Similarly, no signiﬁcant differences
were observed in the medial or lateral subchondral bone plate
thickness between WT and Cnr2/ mice (Table III).
Effect of Cnr2 deﬁciency on proteoglycan production by articular
chondrocytes
In order to gain an insight into the potential mechanism by
which Cnr2 might predispose to osteoarthritis we performed anin vitro experiment in which we compared levels of proteoglycan
production from cultured articular chondrocytes derived from
Cnr2/ mice and wild type littermates. This showed that Cnr2/
derived chondrocytes produced signiﬁcantly less proteoglycans
than wild type chondrocytes (Fig. 4).
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In order to gain an insight into the overall effect of the Cnr2
pathway in the pathogenesis of osteoarthritis, we performed a
meta-analysis of the in vivo studies reported in this paper. Indi-
vidually all three experiments yielded results favouring a role of the
Cnr2 pathway in osteoarthritis with a pooled effect-estimate mean
difference of 1.55 (95% conﬁdence interval [CI]: 0.96, 2.14;
P < 0.00001) with no evidence of heterogeneity between studies
(I2¼ 0%, P¼ 0.46) (Fig. 5). This provides strong evidence in favour of
a pathogenic role for Cnr2 in the pathogenesis of osteoarthritis.
Discussion
Over recent years there has been increasing interest in the po-
tential role of cannabinoids and their receptors in the pathophys-
iology and treatment of joint diseases25. Cannabinoid receptors are
expressed in bovine articular chondrocytes10 and in human syno-
vial tissue11,26 along with the enzyme fatty acid amide hydrolase
(FAAH) which is responsible for degradation of cannabinoids and
other fatty acid amides11. Clinical studies have shown that the
endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol
(2-AG) are present in the synovial ﬂuid of OA and RA patients but
not in synovial ﬂuid from normal volunteers11. Furthermore,
various cannabinoid receptor ligands have been found to reduce
cartilage damage and attenuate tissue injury in mouse models of
inﬂammatory arthritis8,9 and to inhibit IL-1 induced degradation of
cartilage matrix in vitro10. In addition, both receptors have been
shown to play signiﬁcant roles in the regulation of bone turnover
and bone density in mice3e7,27,28.
Despite this, the possible role of cannabinoids and their re-
ceptors in the pathogenesis of osteoarthritis has not previously
been investigated, forming the rationale for the studies presented
here.
Our studies showed that mice with targeted deletion of Cnr2
developed signiﬁcantly more severe osteoarthritis affecting the
medial joint compartment following DMM as compared with wild
type littermates. Although the scores that were observed in this
study are lower than those previously reported in 129/SvEv mice16
this is in keeping with previous observations which have suggested
that C57BL/6 mice may be less susceptible to OA than some other
mouse strains29. Further evidence in favour of a pathogenic role for
the type 2 cannabinoid receptor in DMM induced osteoarthritis
came from the observation that treatment with HU308, an agonist
of CB2 partially protected against the development of osteoarthritis
in wild type mice. While the protective effects were predominantly
observed in the medial joint compartment, the effect remained
signiﬁcant when scores were combined for the whole joint. InFig. 5. Meta-analysis on the role of Cnr2 pathway on osteoarthritis. Meta-analysis of the in
osteoarthritis. The mean and standard deviation (SD) of the OARSI scores from individual ex
for each experiment and the bars represent the 95% conﬁdence intervals. The weight indica
the summary effect from all three experiments combined. Heterogeneity was tested usingcontrast, HU308 had no protective effect in Cnr2/mice subjected
to DMM which is consistent with the hypothesis that HU308 pro-
tected against OA by a Cnr2 speciﬁc mechanism. The importance of
the pathway in the pathogenesis of osteoarthritis is further sup-
ported by the ﬁnding that 12 month old Cnr2/ female mice that
had not undergone any speciﬁc experimental procedures devel-
oped more severe osteoarthritis as compared with wild type lit-
termates. Finally a meta-analysis which combined the results of all
three in vivo experiments showed convincing evidence in favour of
a pathogenic role for Cnr2 in osteoarthritis with no heterogeneity
between studies.
Although these experiments provide strong evidence to sug-
gest that the Cnr2 pathway plays a role in osteoarthritis, further
work will be required to investigate the mechanisms responsible.
We had initially considered that the altered susceptibility to OA
might be mediated by differences in the structure of subchondral
bone, given that previous studies have shown that Cnr2 regulates
bone mass and bone turnover6,7. Although we found subtle dif-
ference in subchondral bone between non-operated Cnr2/ and
wild type mice, there were no differences genotypes following
DMM. Similarly, no differences in subchondral bone were
observed between genotypes in 12 month old mice. The lack of an
effect of DMM on subchondral bone reported in this study con-
trasts with the observations made by Kim and colleagues who
reported that DMM is associated with an increase in trabecular
bone volume of subchondral bone in the medial but not lateral
joint compartment in C57BL/6 mice30. It is possible that technical
factors might have been responsible since the MicroCT was carried
out in the transverse plane as opposed to the coronal plane used
here. In addition Kim et al. analysed the medial and lateral com-
partments separately, whereas we analysed the whole of the tibial
plateau.
A possible explanation for the increased susceptibility of Cnr2/
mice to osteoarthritis would be differences between genotypes in
chondrocyte function or matrix production. In support of this hy-
pothesis, we found that cultured chondrocytes from Cnr2/ mice
produced less proteoglycans in vitro than wild type chondrocytes.
This raises the possibility that deﬁciency of Cnr2 might predispose
to OA by altering the proteoglycan content of cartilage matrix,
rendering it less able to deal with biomechanical stimuli. However,
we cannot exclude the possibility that other mechanisms may also
contribute and so further work will be required, possibly using
tissue speciﬁc inactivation of Cnr2 to determine if the mechanism is
chondrocyte speciﬁc or if other joint tissues are involved.
In this regard, it is relevant to point out that an effect of Cnr2 on
innervating neurons may also be operative, given that activation of
CB2 has been shown to have anti-nociceptive effects in various
experimental pain models31,32,33.vivo experiments performed in this study to evaluate the role of the Cnr2 pathway in
periments are shown. The squares represent the point estimate of the mean difference
tes how much inﬂuence each study has on the overall results. The diamond represents
the Cochran Q-statistic (chi-square) and quantiﬁed using the I2-statistic35.
A. Sophocleous et al. / Osteoarthritis and Cartilage 23 (2015) 1586e1594 1593The question also arises as to whether the increased suscepti-
bility to OA was a direct consequence of Cnr2 inactivation or
changes in expression of other genes and pathways that are regu-
lated by Cnr2. In this regard we have previously shown that dele-
tion of Cnr2 is associated with alterations in the patterns of
expression of many genes some of which are located close to the
site of the targeting event on chromosome 434. While it is possible
that some of the effects we observedwere indirect andmediated by
changes in expression of genes regulated by Cnr2, the protective
effect that we observed in response to HU308 treatment suggests
that signalling through the Cnr2 receptor itself plays an important
role.
Whatever the underlying mechanism, the present studies
demonstrate for the ﬁrst time that the CB2 pathway plays a role in
the pathogenesis of osteoarthritis in mice. While further research
will be required to investigate the mechanisms responsible, our
studies raise the possibility that manipulation of this pathway
might be of therapeutic value in humans with the disease.
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